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Background: Following breast-conserving surgery and post-operative 3D-conformal accelerated partial
breast irradiation (APBI), suboptimal cosmetic results have been reported. Preoperative radiation delivery
to the intact tumor enables better target visualization and treatment volume reduction. Single dose pre-
operative APBI has the potential to improve toxicity profiles, reduce treatment burden and enable in vivo
exploration of breast cancer radiogenomics.
Purpose: Develop practical guidelines for single dose external beam preoperative APBI.
Methods: Recommended dose constraints were derived from pooled dosimetry estimates from 2 clinical
trials. In an American dose escalation trial, a uniform 15, 18 or 21 Gy dose has previously been evaluated
for non-lobular cT1N0 or low/intermediate grade DCIS <2 cm in prone position (n = 32). In the
Netherlands, the feasibility of ablative APBI (20 Gy to GTV, 15 Gy to CTV) to non-lobular cT1N0 in supine
position, is currently being explored (n = 15). The dosimetric adherence to the developed constraints was
evaluated in new APBI plans with a 21 Gy uniform dose but an extended CTV margin (n = 32).
Results: Dosimetric data pooling enabled the development of practical guidelines for single dose preop-
erative APBI.
Conclusion: The developed guidelines will allow further explorations in the promising field of single dose
preoperative external beam APBI for breast cancer treatment.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
Accelerated partial breast irradiation (APBI) has been explored
as an alternative to whole breast irradiation (WBI) following
breast-conserving surgery [1–9]. In selected patients with early-
stage breast cancer and low-risk of local recurrence, APBI efficacy
appears to be equivalent to WBI with respect to local control and
survival rates [3,6–10].
Several randomized controlled trials have evaluated different
approaches to deliver APBI following breast-conserving surgery,
each with its own advantages and disadvantages. Interstitial mul-
ticatheter brachytherapy (IMB) is the technique with the longest
clinical follow-up available and good clinical results when com-
pared to WBI with equivalent efficacy, and comparable toxicity
profiles [6,9]. However, due to the invasiveness of the technique,
the required physician’s expertise and brachytherapy equipment,
IMB has not been widely implemented. Second, intra-operative
radiotherapy (IORT) is an appealing technique due to the single
treatment approach at the time of surgery but requires costly
and cumbersome equipment. External beam APBI has the advan-
tage of widespread equipment availability and expertise, but when
compared to the previous techniques, larger treatment volumes
have typically been utilized. As a result, an increase in soft tissue
fibrosis and suboptimal cosmetic outcomes has been seen with
3-dimensional conformal external beam radiation therapy (3D-
CRT) [4]. However, more dose conformal techniques such as
intensity-modulated radiotherapy (IMRT), have the potential for
superior toxicity and cosmetic outcome profiles when compared
to WBI, suggesting that the results of external beam APBI could
be improved upon [8].
In an effort to overcome the disadvantages and capitalize on
the advantages of the previous APBI techniques, the concept of
MRI-guided single dose external beam partial breast irradiation
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delivered prior to surgical resection has been developed [11–13].
The single dose concept of IORT using a non-invasive external
beam technique can minimize the treatment duration and bur-
den for patients, without the purchase of any supplementary
radiotherapy equipment. In addition, the delivery of radiation
(RT) preoperatively to the intact tumor allows more precise tar-
geting when compared to post-surgery, resulting in significantly
smaller treatment volumes and possibly less RT-induced toxicity
[11,14]. Another advantage of preoperative APBI concerns the
uniformity of treatment volume definition, with less interobserver
variation in target volume delineation when compared to a postop-
erative approach [15]. MRI-guided preoperative target definition
can further improve the tumor visualization (i.e. tumor spiculae)
[16]. This could facilitate dose escalation, enabling an ablative,
definitive treatment approach for early-stage breast cancer. Finally,
preoperative APBI allows the direct evaluation of RT effects in
breast tumors, aiming at the identification of radiation response
predictors and biomarkers, which may help to guide personalized
treatment for future patients [17].
Single dose external beam preoperative APBI has great potential
in clinical practice to deliver a precise and uniform, minimally bur-
densome treatment with less associated toxicity, and opens a new
window of opportunity in radiogenomics. Based on the clinical
experience with this approach in two university medical centers,
this manuscript introduces practical guidelines for the delivery of
single dose external beam preoperative radiotherapy.
Methods
Study population
The current study includes data from 2 pre-existing studies and
was approved by the Institutional Review Boards of the participat-
ing institutes.
In both trials, toxicity was prospectively evaluated at predefined,
overlapping time points using the Cancer Institute’s Common Termi-
nology Criteria for Adverse Events (CTCAE version_4.03).
At Duke University Medical Center, Durham, Unites States of
America, a phase I dose escalation trial (ClinicalTrial.gov
NCT00944528) was conducted between August 2010 and March
2013 in order to determine the maximum tolerated dose of single
dose preoperative APBI in prone RT position. A total of 32 patients
55 years with cT1N0 invasive ductal carcinomas or DCIS 2.0 cm
were included [12]. A lumpectomy was performed within 10 days
following RT. The updated treatment toxicity at a median of
37 months follow-up is in line with the previous published results,
with chronic grade 1–2 local fibrosis, dermatitis and breast pain
being the most common toxicities. In all patients treated with sin-
gle dose APBI only, good to excellent cosmetic outcomes were
assessed by the treating physician.
At the University Medical Center Utrecht, The Netherlands, an
ongoing trial evaluates the clinical feasibility of a radiosurgical
approach for early-stage breast cancer (ClinicalTrial.gov
NCT02316561). A lumpectomy is performed at 6 months following
RT in the supine position, in order to evaluate the primary end-
point, the pathological response. The current study included the
first 15 study patients 50 years with cT1N0(sn) invasive ductal car-
cinoma. At time of analysis, eleven (of the planned 25) patients had
a lumpectomy performed, and only grade 1–2 toxicity has been
observed at a median follow-up of 7 months (Appendix Table A1).
Treatment planning
At Duke, IMRT was used to deliver 15 Gy, 18 Gy or 21 Gy to the
gross tumor volume (GTV) and the clinical target volume (CTV)
(Eclipseversion 10). At Utrecht, a single dose Volumetric Modulated
Arc Therapy (VMAT) treatmentwas concomitantly prescribed to deliver
two dose levels, 20 Gy to the GTV and 15 Gy to the CTV (Monacover-
sion 19). Study details have been previously published [12,13,18].
Table 1 and Fig. 1 illustrate treatment planning characteristics.
Guidelines development
Since the initial dosimetric parameters of interest differed
between the institutions, a new protocol for treatment plan evalu-
ation was reached in consensus. Using the original treatment plans,
this protocol evaluated target volume coverage and dose to organs
at risk (OAR) with respect to NSABP B39/RTOG 0413 and QUANTEC
guidelines for target and normal tissue constraints, converted to a
single-dose prescription [13,19]. Furthermore, in order to achieve a
uniform evaluation between institutions the chest wall delineation
was adjusted, and two different skin definitions were assessed (i.e.
first 3 and 5 mm subcutaneous tissue).
Since no dose limiting toxicity has been encountered, no normal
tissue complication probability curves were developed. Reasonable
constraints were pragmatically defined based on descriptive statis-
tics of the pooled dosimetric parameters in the clinical cohorts.
Overall median, interquartile range (IQR) and 10th and 90th per-
centile doses were determined for target volume and OAR parame-
ters. Optimal and acceptable dosimetry was defined as an OAR
value that did not exceed the 75th (upper IQR) and 90th percentile
of the pooled dosimetric parameter, respectively.
Dosimetric feasibility guidelines
To determine the feasibility of these new dose constraints for
future studies, new treatment plans were performed for the
patients in the dose escalation cohort (n = 32) using Eclipseversion
13.6. Given the variation in breast delineations, some ipsilateral and
contralateral breast contours were adjusted, following consensus
[20]. A uniform 21 Gy dose was prescribed to the intact tumor with
a 2.0 cm margin in order to assess our guidelines using a larger CTV
margin that more closely approximates existing post-operative
external-beam APBI data. Due to the 0.5 cm CTV extension from
the initial treatment plans, this would more often align the skin.
Adequate target volume coverage was therefore defined as 95%
of prescription dose to 98% of the CTV. Table 1 illustrates RT plan-
ning characteristics for this replanned cohort. The new plans were
evaluated for adherence to the previously defined optimal or
acceptable dosimetry from the clinical cohorts.
Results
Dosimetry across cohorts
The median GTV and CTV receiving 95% of the prescribed dose
(PD) was 99% in all 3 cohorts. The median PTV receiving 95% of
the PD was 97% in the clinical cohorts and 95% in the replanned
cohort. Table 2 gives an overview of the treatment volumes. In the
integrated boost cohort treatment volumes are larger compared to
the dose escalation cohort, given the 0.5 cm additional CTV exten-
sion. When evaluating PTV overdosage in relation to the CTV PD in
the integrated boost cohort, the median V110% and V105% was 29%
and 43%, respectively. Table 3 illustrates the dosimetry across the
various clinical cohorts. Higher mean ipsilateral breast and skin
dosimetry are encountered with higher PD. Lower PD fall-off is
observed in the integrated boost cohort.
Optimal or acceptable plan dosimetry
Optimal and acceptable dosimetry was defined from the clinical
cohorts as a value up to the 75th percentile (i.e. upper IQR) and
8 R.K. Charaghvandi et al. / Clinical and Translational Radiation Oncology 6 (2017) 7–14
90th percentile of the pooled dosimetric parameter, respectively
(Table 4). Table 5 summarizes treatment recommendations for sin-
gle dose preoperative APBI.
Dosimetric adherence to constraints
In the replanned cohort, at least acceptable V100% and V50% PD in
the ipsilateral breast was achieved in 100% and 91% of the cases
despite smaller consensus breast volumes (Table 2). An acceptable
mean ipsilateral breast dose was evaluated in 56% of the patients.
Optimal dosimetry was achieved for the contralateral breast, ipsi-
lateral lung and chest wall in 97%, 94% and 97% of cases, respec-
tively. At least acceptable Dmax and Dmean heart was encountered
in 97% and 100% of patients. For the first 3 mm of subcutaneous tis-
sue, at least acceptable skin dosimetry was achieved for the D1cc
and D10cc in 19% and 63% of cases, respectively. For the first
Fig. 1. Dose distributions treatment. (A) VMAT plan in supine treatment position with 20 Gy prescription dose (PD) to the gross tumor volume (GTV) and 15 Gy PD to the
clinical target volume (CTV). Isodose illustrate the GTV prescription dose. (B) IMRT plan in prone treatment position plan with 21 Gy prescription dose (PD) and a 15 mm CTV
margin. (C) IMRT plan in prone treatment position plan with 21 Gy prescription dose (PD) and a 20 mm CTV margin.
Table 1
Overview of treatment planning in the different cohorts.
Dose escalation cohort 15, 18 or 21 Gy (total n = 32) Integrated boost cohort 20/15 Gy (n = 15) Replanned cohort 21 Gy (n = 32)
Set-up Prone* Supine Prone*
Gross tumor
volume (GTV)
Delineated based on fused CT-MR findings and
intratumoral fiducial marker
Delineated based on fused CT-MR findings
and intratumoral fiducial marker
Delineated based on fused CT-MR findings
and intratumoral fiducial marker
Clinical target
volume (CTV)
15 mm around GTV, excluding the first 5 mm from
the body as well as chest wall, if greater than 1 cm
from the GTV
20 mm around GTV, excluding the first
5 mm from the body as well as the chest
wall
20 mm around GTV, excluding the first
5 mm from the body as well as the chest
wall
Evaluated planning
target volume
(PTV)
3 mmmargin from CTV, excluding the first 5 mm of
subcutaneous tissue
– 3 mm margin from CTV, excluding the
first 5 mm of subcutaneous tissue
(PTV(CTV))
– 3 mm margin from GTV, excluding the
first 5 mm of subcutaneous tissue
(PTVGTV)
3 mm margin from CTV, excluding the first
5 mm of subcutaneous tissue and chest wall
Prescription dose
(PD)
15, 18 or 21 Gy to the CTV 15 Gy for the CTV
20 Gy for the GTV
21 Gy for the uniform CTV
Definition adequate
coverage
At least 95% of PD to 100% of CTV At least 95% of PD to at least 99% of PTVCTV
or PTVGTV, respectively
At least 95% of PD to at least 98% of CTV
Secondary objective: 95% of PD to 95% of
PTVCTV
Treatment planning
approach
Intensity modulated radiation therapy with 5–7
(non)coplanar beam arrangement
Volumetric modulated arc therapy with 2
partial arcs
Intensity modulated radiation therapy with
4–7 noncoplanar beam arrangement
* 2 patients were treated supine.
Table 2
Treatment volume characteristics in the clinical and replanned cohorts.
Dose escalation prone cohort 15, 18, 21 Gy
(N = 32) median (IQR)a
Integrated boost supine cohort 15/20 Gy
(N = 15) median (IQR)a
Replanned prone cohort 21 Gy
(N = 32) median (IQR)a
Affected breast n (%)
Left 18 (56%) 7 (47%) 18 (56%)
Right 14 (44%) 8 (53%) 14 (44%)
Ipsilateral breast volume (cc) 1589.6 (1098.1–1887.0) 1099.9 (821.1–1245.0) 1470.9b (974.7–1727.3)
Treatment volumes
Gross tumor volume (cc) 0.9 (0.5–1.3) 1.3 (1.0–2.9) 0.9 (0.5–1.3)
Clinical tumor volume (cc) 43.2 (35.0–49.3) 74.1 (69.4–96.0) 75.6 (64.2–88.4)
Planning target volume (cc) 63.3 (54.3–73.5) 107.4 (97.0–154.9) 101.4 (85.3–122.6)
Ratio PTV to ipsilateral breast volume (%) 4.6 (2.9–5.5) 12.8 (8.5–13.8) 8.1 (4.9–9.5)
Overdosage
V105% PTV (%) 7.3 (0–35.8) 0c (0–0) 0 (0–0.2)
V110% PTV(%) 0 (0–0) 0c (0–0) 0 (0–0)
Dmax PTV(%) 106.8 (105.6–109.7) 104.5c (104.0–105.5) 103.2 (101.8–104.7)
a Unless otherwise specified.
b Represents consensus breast volumes.
c 105% (21 Gy) and 110% (22 Gy) respectively of the prescription dose to the GTV in the PTV(CTV) (thereby excluding the GTV).
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5 mm of subcutaneous tissue, this was achieved in 19% and 28% of
patients, respectively.
Discussion
The current study provides consensus recommendations for
single dose preoperative APBI target and OAR constraints based
on the clinical data from 2 university medical centers (Table 5,
Appendix Fig. A1). Optimal and acceptable dose constraints were
formulated from clinically correlated data. In patients treated with
preoperative single dose APBI only, no dose limiting toxicity has
been observed, possibly placing these constraints at the lower, safe
end of the toxicity spectrum [12], Appendix Table A1. In addition,
the dosimetric feasibility of single dose 21 Gy APBI with CTV mar-
gin expansion was evaluated. Acceptable and optimal OAR dosime-
try could be achieved in the great majority of the cases, except for
the skin, with at least acceptable metrics ranging from 19 to 63%.
Additional target volume expansion would likely preclude use of
skin constraint and require additional clinical investigation to
determine the impact of high skin doses on acute and chronic tox-
icity (Appendix Fig. A2).
To our knowledge, no other centers have evaluated the feasi-
bility of single dose preoperative external beam APBI. Single dose
18-21 Gy 3D-CRT based APBI following surgery has been previ-
ously reported for pT1–2(max.3cm)N0–1 non-lobular carcinoma
(n = 64) [21]. The study stopped prematurely due to unexpected
grade 2–3 subcutaneous fibrosis and fair-poor cosmesis in
44% and 41% of the patients, respectively. This is in contrast to
our results and is likely due to our smaller preoperative
target volumes. For example, our median PTV was 72.2 cc
(30.1–203.7 cc) versus 96 cc (range 17–290 cc) compared to the
post-lumpectomy APBI study. Furthermore, increased toxicity
in the post-lumpectomy 3D-CRT based APBI could be explained
by differences in techniques, with less dose inhomogeneity for
the IMRT-VMAT approach used at our institutes [22]. Also, we
hypothesize that preoperative APBI is more favorable with
respect to the cosmesis because a portion of the breast tissue
receiving high-dose RT prone to development of fibrosis will be
excised. In the post-lumpectomy APBI study, a mean ipsilateral
breast dose 9 Gy was the only factor associated with impaired
cosmesis. Their mean dose was 9.7 Gy (range 4.4–14.1 Gy),
whereas the pooled mean estimate in the clinical cohorts was
3.8 Gy (range 1.6–7.8 Gy) and 5.0 Gy (range 2.9–7.3 Gy) in the
replanned cohort.
Table 3
Dose to organs at risk across the clinical cohorts.
Dose escalation prone cohort
15 Gy (N = 8) median (IQR)
Dose escalation prone cohort
18 Gy (N = 8) median (IQR)
Dose escalation prone cohort
21 Gy (N = 16) median (IQR)
Integrated boost supine cohort
15/20 Gy (N = 15) median (IQR)
Ipsilateral breast
V100% CTV prescription dose (%) 4.2 (3.1–4.9) 3.2 (2.2–3.7) 4.2 (2.5–5.9) 10.2 (6.8–11.0)
V50% CTV prescription dose (%) 14.4 (10.3–17.6) 11.6 (8.7–14.1) 14.2 (10.1–19.7) 27.3 (19.6–30.7)
V100% GTV prescription dose (%) ** ** ** 0.4 (0.3–0.8)
V50% GTV prescription dose (%) ** ** ** 21.9 (15.8–24.0)
Mean dose (Gy) 2.9 (2.2–3.3) 2.8 (2.4–3.0) 3.8 (2.8–4.7) 5.0 (4.0–5.4)
Skin (3 mm)*
D1cc (Gy) 8.8 (7.1–10.9) 10.6 (9.1–11.9) 12.5 (10.9–15.8) 12.9 (11.6–13.3)
D10cc (Gy) 5.9 (4.4–6.6) 7.2 (6.2–8.3) 7.8 (7.0–9.1) 9.7 (7.7–10.5)
Skin (5 mm)*
D1cc (Gy) 12.1 (9.0–12.9) 12.9 (11.4–15) 17.1 (15.9–18.8) 14.5 (13.3–15.8)
D10cc (Gy) 7.9 (6.3–8.9) 9.5 (8.5–10.4) 11.6 (10.6–13.9) 12.3 (10.4–12.7)
Heart
Dmax (Gy) 3.1 (1.0–4.0) 1.6 (0.5–3.0) 0.8 (0.3–2.4) 3.0 (1.9–3.9)
Mean dose (Gy) 0.1 (0.0–0.2) 0.2 (0.0–0.5) 0.1 (0–0.2) 0.7 (0.5–1.2)
Other
Dmax contralateral breast (Gy) 1.2 (0.2–2.2) 0.3 (0.2–1.1) 0.4 (0.3–0.7) 1.5 (0.8–3.1)
Mean dose ipsilateral lung (Gy) 0.2 (0.1–0.5) 0.2 (0.1–0.4) 0.4 (0.2–0.6) 1.4 (0.9–1.6)
D20cc dose chest wall (Gy) 2.8 (1.7–7.7) 2.4 (1.0–4.0) 3.9 (2.4–5.0) 12.3 (9.4–13.4)
* The first 3 mm or 5 mm of subcutaneous tissue from body surface.
** CTV prescription dose is GTV prescription dose.
Table 4
Dose to organs at risk in the pooled (clinical) cohort of patients, and in the replanned
21 Gy cohort.
Clinical cohorts 15, 18,
21 (prone) and
15/20 Gy (supine)
median (IQR)
[10th–90th percentile]
(N = 47)
Replanned
prone
cohort 21 Gy
median
(IQR) (N = 32)
Ipsilateral breast
V100% CTV prescription dose (%) 4.6 (3.1–7.2)
[2.1–10.8]
1.4 (0.1–6.6)
V50% CTV prescription dose (%) 16.3 (12.1–20.9)
[8.2–29.8]
20.0 (16.0–
26.7)
Mean dose (Gy) 3.6 (2.8–4.8)
[2.3–5.4]
5.2 (4.2–5.8)
Skin (3 mm)*
D1cc (Gy) 11.7 (10.4–13.2)
[8.2–15.3]
16.4 (15.6–
17.0)
D10cc (Gy) 7.7 (6.6–9.5)
[5.7–10.6]
10.2 (9.1–
11.0)
Skin (5 mm)*
D1cc (Gy) 14.5 (12.5–16.3)
[11.0–18.2]
19.0 (18.4–
19.4)
D10cc (Gy) 10.5 (9.0–12.4)
[7.7–13.9]
15.4 (13.7–
16.0)
Heart
Dmax (Gy) 2.3 (0.8–3.4)
[0.2–4.2]
2.6 (1.0–3.3)
Mean dose (Gy) 0.2 (0.1–0.6)
[0–1.0]
0.2 (0.1–0.4)
Other
Dmax contralateral breast (Gy) 0.5 (0.3–1.6)
[0.2–2.4]
0.2 (0.2–0.5)
Mean dose ipsilateral lung (Gy) 0.4 (0.2–1.0)
[0.1–1.6]
0.6 (0.3–0.7)
D20cc dose chest wall (Gy) 4.6 (2.5–10.2)
[1.3–13.2]
4.1 (3.1–5.6)
* The first 3 mm or 5 mm of subcutaneous tissue from body surface.
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Van der Leij et al. evaluated preoperative multiple fraction APBI
for cT1–2(max.3.0cm)N0 (n = 70) by delivering forty Gy in 10 fractions
over 2 weeks with 3D-CRT, IMRT or VMAT, followed by lumpec-
tomy at 6 weeks [23]. Interestingly, induration fibrosis actually
declined over time and cosmetic outcome improved. At 24 months,
46% and 2% of the patients experienced mild-moderate local
Table 5
Treatment planning recommendations for single dose preoperative external beam partial breast irradiation.
DEFINITION RECOMMENDATION or 
CONSTRAINTS
POOLED CONSTRAINT
(IQR) [10th-90th percenle]
ELIGIBILITY
Paent characteriscs - - women ≥ 50 years of age
- eligible for breast conservaon 
treatment
-
Tumor characterisc - - unifocal non-lobular cT1N0Mx
or low/intermediate grade 
cTisN0Mx ≤2cm
- ER or PR receptor posive
- Her2 negave
- 
TARGET VOLUMES
Prescripon dose (PD) - - 15 to 21 Gy uniform dose, in 
case of short interval (≤ 10
days) to surgery
- the recommended dose and 
interval to surgery for a 
radiosurgical approach is 
currently under evaluaon in the 
integrated boost cohort. 
(ClinicalTrial.gov NCT02316561)
- 
GTV Delineaon according to 
ﬁndings on fused contrast-
enhanced CT-MRI. 
Aim at:
- ≥ 95% dose to 99% volume 
- Dmax ≤ 107%
CTV -uniform PD: 1.5 to 2.0cm 
 -integrated boost approach:  
2.0cm  
 -ﬁrst 5mm of subcutaneous 
ssue and chest wall are 
excluded. 
Aim at:
- ≥ 95% dose to 98% volume 
- uniform PD: Dmax ≤ 110%
- Dmax ≤ 140% with an integrated 
boost approach
- 
Planning target volume 
(PTV) [18, 32]
- uniform PD: 3mm  expansion 
from CTV
-  integrated boost approach:  
addional 3mm expansion 
from GTV.
Aim at:
- ≥ 95% dose in ≥97% volume
- Dmax < 110%
- 
- ﬁrst 5 mm of subcutaneous 
ssue are excluded.
ORGANS AT RISK 
Ipsilateral breast [20] According to radiopaque wire 
markings of breast ssue 
following palpaon, as well as 
breast contouring atlas 
guidelines
Aim at:
- ≤ 8.5% PTV to breast rao 
- ≤ 4.8Gy mean dose
- V100% CTV PD ≤7.2%
- V50% CTV PD ≤20.9%
(3.5-8.5); [2.0-13.8]
Rao PTV/breast 
(2.8-4.8); [2.3-5.4]
Mean breast dose
(3.1-7.2); [2.1-10.8]
V100% CTV PD 
(12.1-20.9); [8.2-29.8]
V50% CTV PD (%) 
Skin The ﬁrst 3 to 5 mm  of 
subcutaneous ssue of the 
ipsilateral breast.
Aim at:
- Dmax ≤ 100% PD
- 3 mm: D1cc ≤ 13.2Gy
- 3 mm: D10cc ≤ 9.5Gy
- 5 mm: D1cc ≤ 16.3Gy
- 5 mm: D10cc ≤ 12.4Gy
D1cc (10.4-13.2); [8.2-15.3]
Skin 3 mm
D10cc (6.6-9.5); [5.7-10.6]
D1cc (12.5-16.3); [11.0-18.2]
Skin 5 mm
D10cc (9.0-12.4); [7.7-13.9]
Chest wall Sternum, ribs and (intercostal, 
pectoralis) muscles aligning 
the ipsilateral breast. 
Aim at:
- D20cc ≤ 10.2Gy
D20cc
(2.5-10.2) 
[1.3-13.2]
Heart [33] The heart contour starts below 
the pulmonary trunk 
bifurcaon and includes the 
pericardium. 
Aim at:
- mean dose ≤0.6Gy
- Dmax ≤3.4Gy
(0.1-0.6); [0-1.0]
Mean dose
(0.7-3.4); [0.2-4.2]
Max dose
Contralateral breast [20] According to ﬁndings on CT-
scan as well as breast 
contouring atlas guidelines, 
not extending past midline. 
Aim at:
- Dmax ≤1.6Gy 
Dmax
(0.3-1.6) 
[0.2-2.2]
Lungs Delineaon of ipsilateral, 
contralateral and both lungs 
according to CT ﬁndings. 
Aim at mean dose:
- ipsilateral lung ≤ 1.0Gy
- contralateral lung ≤ 0.4Gy
- both lungs ≤ 0.7Gy
(0.2-1.0); [0.1-1.6]
Mean dose ipsilateral
(0-0.4); [0-0.5]
Mean dose contralateral
(0.2-0.7); [0.1-1.0]
Mean dose both lungs 
Value: opmal organ at risk constraint Value: acceptable organ at risk constraint
(See above-mentioned references for further information.)
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fibrosis and 80% were satisfied to very satisfied with the cosmetic
result. A phase 2 trial by Nichols et al. evaluated 3D-CRT preoper-
ative APBI for T1–2(max.3.0cm)N0 (n = 27) with 38.5 Gy in 3.85 Gy frac-
tions twice daily and lumpectomy performed 21 days after RT
[24]. At a median follow-up of 3.6 years, good–excellent cosmetic
outcome was reported by 78% of women. Expected grade 0–1 tox-
icity (CTCAE_version_3), such as fatigue, skin erythema, hyperpig-
mentation, fibrosis, breast discomfort, edema and dyspnea was
encountered. A direct comparison with our cohorts is difficult
due to fractionation and/or RT technique differences, nonetheless,
these studies show that preoperative APBI is a feasible option for
low-risk breast cancer patients and give a sense of expected clini-
cal outcomes.
Furthermore, our clinical preoperative irradiated cohorts illus-
trate a great advantage in target volume reduction compared with
postoperative APBI. In the APBI-arm of the RAPID trial, women
40 years with pT1–2(max 3.0cm)N0 were treated to a total of
38.5 Gy in twice daily 10 fractions following breast-conserving sur-
gery [4,25]. The mean volume receiving 95% of PD was 332 cc
(standard deviation (SD) 153 cc), with a mean ratio to ipsilateral
breast of 22% (SD 7%). In our clinical cohorts, the mean PTV volume
was 72 cc (SD 37 cc) with a mean 7% (SD 4%) PTV to ipsilateral
breast ratio. Even in the replanned cohort with an extended CTV
margin, the mean PTV was 99 cc (SD 31 cc) with a mean 8% (SD
3%) ratio PTV to ipsilateral breast. We therefore believe that preop-
erative external beam APBI has great potential in clinical practice
to deliver a precise treatment with smaller treatment volumes,
enabling a reduction in RT associated toxicity and improvement
in treatment burden.
To our knowledge, no other clinical studies assessed skin toxic-
ity following single dose RT. Setting constraints based on data from
hyperfractionated or multiple fraction hypofractioned treatment
would not be appropriate from a radiobiological point of view. If
acceptable skin dosimetry cannot be achieved in clinical practice,
a reduction of the CTV margin from 20 to 15 mm could provide
an alternative in order to still deliver a single dose treatment.
Another option to consider when skin constraints cannot be
achieved, is accepting a higher dose given that no dose limiting
toxicity has been observed so far. It should be noted though that
additional single dose RT clinical studies are needed to determine
whether larger target volumes with higher associated skin doses
maintain clinically acceptable skin toxicity.
With postoperative APBI, the CTV definition has mainly evolved
from Holland’s work in mastectomy specimens, where even in
small tumors 2.0 cm, 92% of microscopic disease extended up
to 30 mm from the index lesion [26]. Nowadays, an MRI of the
breasts is typically utilized to assess the possibility of extensive
disease in APBI candidates, resulting in 11% of patients eventually
deemed ineligible [27]. An MRI and histopathology correlation
study showed that in the absence of extensive intraductal compo-
nent, no subclinical invasive disease was present in 93% of lumpec-
tomy cases more than 10 mm beyond the edge of the lesion as
measured on MRI [28]. In a recent prospective pathology study
on the appropriate CTV margin for APBI, the maximum radial
extension of residual carcinoma was assessed in 133 women
requiring re-excision or completion mastectomy after initial
lumpectomy [29]. In the 58% patients with non-involved initial
margins, residual disease, if present, was 10 mm in 97.4% of the
cases. In the 42% patients with involved margins, disease extended
beyond 20 mm in 10.7% of cases. Large extension of microscopic
disease was associated with involved margins, tumorsize
30 mm and premenopausal status, which are characteristics that
do not apply to our patient population. We acknowledge that the
appropriate preoperative CTV margin is a subject up for debate,
however for low-risk patients with biologically favorable and lim-
ited extent of disease assessed on MRI, we perceive 15 mm as a
minimum, up to 20 mm, as a recommended CTV margin [30,31],
Table 5. This is also supported by our clinical outcomes with only
1 local recurrence so far in our dose-escalation cohort at a median
follow-up of 37 months.
Similarly, the optimal time between surgery and resection is
not known. In the dose escalation ‘proof of principle’ trial, the
investigators did not wish to delay definitive surgical resection
and therefore surgery was performed 10 days. In the integrated
boost cohort where a radiosurgical approach is currently explored,
surgery is undertaken 6 months after RT in order to evaluate the
complete pathologic response. Given that the latter approach is
still under investigation, we suggest a short interval to surgery.
The current study has certain drawbacks that should be
addressed. First, the recommended constraints originate from a
heterogeneous population, treated in the prone or supine position,
with a VMAT or IMRT technique, different optimization techniques
and various fractionation schedules. Nonetheless, we believe that
the radiobiological impact of single dose highly-conformal APBI
15 Gy is sufficiently similar, and rare, to justify this pooling of
data. Combining the scarce experience will eventually define the
safety aspects of this treatment approach. Also, this heterogeneous
population reveals variation across different medical centers and
illustrates current clinical practice, that should be considered in
study design. We expect that ongoing and future trials will provide
a sufficient number of patients to enable subgroup analysis. Sec-
ond, the patients in the simultaneous boost cohort have a limited
229 days follow-up. Though toxicity has been limited thus far,
additional data will be required to confirm the safety of treatment
planning with the suggested constraints. Nonetheless, given the
scarce experience with single dose APBI, guidelines to ensure con-
sistent treatment planning will be critical for ongoing assessment
of clinical feasibility with this technique.
We believe single dose preoperative RT is a compelling treat-
ment approach and our practical recommendations could reach
further than a low-risk APBI eligible population. Future studies
could focus on locally advanced breast cancer in conjunction with
immunotherapy, for example [34]. Furthermore, if single dose RT
proves to be ablative for early-stage breast cancer, future studies
could focus on the minimally invasive treatment for functionally
impaired, medically inoperable breast cancer patients. However
to minimize the possibility of adverse events for study patients,
carrying out single dose ultra hypofractionated RT studies should
be confined to stringent protocols, taking pre-existing experience
into account. We perceive our current experience and recommen-
dations a basic, but helpful foundation for future explorations in
the promising field of single dose preoperative RT.
In conclusion, dosimetric data pooling acquired from clinical
cohorts of 15 Gy, 18 Gy, 21 Gy, and simultaneous integrated
15/20 Gy boost, enabled the development of practical guidelines
for single dose preoperative APBI in women 50 years of age with
low-risk cT1N0 non-lobular breast cancer or limited DCIS. The dosi-
metric adherence to developed OAR constraints was demonstrated
in new APBI plans with a 21 Gy uniform dose but an extended CTV
margin. However, caution remains warranted and possible adapta-
tion of skin constraints might be required following future single
dose APBI clinical trials. Our short-term results support the impor-
tance of further developments in the field of single dose preopera-
tive APBI which has the potential to further minimize treatment
burden, reduce target volumes and treatment toxicity, and allow
the in vivo exploration of breast cancer radiogenomics.
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Appendix A
Fig. A1. Recommended delineations organs at risk and target volumes in prone (A) and supine treatment approach (B).
Fig. A2. The impact of CTV increase (from 15 to 20 mm) and 21 Gy prescription dose in the clinical versus replanned prone cohort for D1cc (A) and D10cc (B) in the first 3 mm of
subcutaneous tissue.
Table A1
Overview of main treatment toxicities and post-operative complications following single dose preoperative accelerated partial
breast irradiation in the integrated boost cohort (ClinicalTrial.gov NCT02316561).
Percentage toxicity n = 15 (%)
Toxicity grade 1 (%)
Local fibrosis 87%
Fatigue 80%
Breast discomfort 67%
Dermatitis 0%
Toxicity grade 2 (%)
Pain breast* 13%
Post-operative complications (%)
Haematoma (grade 2) 7%
Chronic seroma **
* Resolved following analgesic treatment and lymphedema therapy.
** Chronic seroma rates cannot be reported due to the limited median follow-up of 69 days following surgery.
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